KRAS and neoplasm: sc-RNAseq, depicting the transcriptional dynamics encompassing tumor response to PTC596, emphasized a strong decrease of the epithelial subpopulations as well as the tumor-specific epithelial cluster, suggesting Kras-mutant tumor is amenable to PTC596 treatment.